MEMehrshad Ebrahimnezhad

Mehrshad Ebrahimnezhad

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mehrshad Ebrahimnezhad has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Biomarkers in Acute Mesenteric Ischemia: A Systematic Review of Diagnostic Performance and Injury-Related Signals

    by Zelimkhan Berikkhanov, Zakhar Akulov, Ekaterina Klimova, David Pogosyan, Evgeniy Tarabrin, Alexey Shestakov, Aleksey Kotelnikov, Andrey Nikolaev, Vadim Razumovsky, Milena Ivanova, et al.

    Background/Objectives: We examined nine biomarkers for acute mesenteric ischemia (AMI) detection, necrosis and postoperative prediction. Methods: PubMed/MEDLINE, the Cochrane Library and indexed citation links were searched on 10 October 2026 without a lower publication-year limit. PubMed and citation searches used an October 2026 publication cutoff. English- and Russian-language clinical reports with at least 10 participants were eligible. Narrative synthesis used QUADAS-2 and diagnostic GRADE. Results: Twenty-nine primary reports were included, with reported cohorts of 18–1479 participants. Cohort overlap and varying tested denominators precluded an unduplicated participant total. Among 28 diagnostic reports, 22 had high index-test risk and 25 had high flow/timing risk. Certainty was very low for eight markers. I-FABP, α-GST and citrulline findings depended on population, assay and timing. D-dimer, lactate, procalcitonin and ischemia-modified albumin lacked intestinal specificity. Urinary I-FABP estimates were imprecise. SM22 supplied association data without diagnostic-performance estimates. Conclusions: No evaluated marker supports reliable stand-alone exclusion of AMI or determination of bowel viability. Complementary panels require prospective validation. The injury diagrams are unvalidated research models.

  • Open Access

    From Bile Dysmetabolism to Lipid–Metabolic Remodeling of the Distal Colon: A Vectorial Concept of Colorectal Carcinogenesis (Part I)

    by Maria A. Sukhanova, Zakhar A. Akulov, Zelimkhan G. M. Berikkhanov, Alexey L. Shestakov, Aleksey G. Kotelnikov, Andrey M. Nikolaev, Vadim S. Razumovsky, Evgeniy A. Tarabrin, Milena Yu. Ivanova, Mehrshad Ebrahimnezhad, et al.

    Colorectal cancer (CRC) is traditionally viewed as the result of the sequential accumulation of molecular alterations and the clonal expansion of transformed cells. However, the state of morphologically non-neoplastic mucosa preceding the development of neoplasia remains considerably less well characterized. This narrative review aims to integrate evidence on biliary and lipid metabolism, intestinal transit, microbial metabolism, and field cancerization and to formulate a testable model of early metabolic remodeling in the distal colon. We propose that a chronically altered biliary–metabolic environment, combined with prolonged luminal and mucosa-associated exposure, may promote lipid–metabolic remodeling of morphologically non-neoplastic mucosa. This state is considered not as a new disease entity but as a potential tissue phenotype capable of altering the barrier, metabolic, and regenerative properties of the epithelium. Subsequent exposure to nitrogen-containing products of microbial metabolism may sustain repeated cycles of injury and regeneration, thereby creating conditions for clonal selection. Following the emergence of a neoplastic clone, the same local environment may potentially assume a different biological role and become part of a metabolic niche that supports further clonal expansion. The proposed model extends the concept of field cancerization by incorporating a metabolic dimension and generates a series of spatial and temporal predictions amenable to experimental and prospective clinical testing. Validation of this model may provide a basis for investigating morphologically non-neoplastic mucosa as potential tissue at risk and for developing earlier preventive and diagnostic approaches.

  • Open Access

    Bile Biochemistry as a Therapeutic Target in Biliary Surgery: Disease-Specific Evidence and Clinical Limits

    by Zelimkhan Berikkhanov, Zakhar Akulov, Mihail Emcev, Evgeniy Tarabrin, Alexey Shestakov, Aleksey Kotelnikov, Andrey Nikolaev, Vadim Razumovsky, Milena Ivanova, Mehrshad Ebrahimnezhad, et al.

    Background/Objectives: Bile acid therapies have expanded treatment options for cholestatic disease, but their relevance to biliary surgery depends on the diagnosis and endpoint. This critical narrative review examines where molecular evidence changes care and where surgical applications remain untested. Methods: The existing synthesis was supplemented by targeted literature searches and regulatory checks completed on 20 September 2026. Studies were assessed by design, population, outcome, and applicability to surgical decisions. Results: Genetic assessment can identify inherited cholestasis or selected recurrent lithogenic disorders that persist after anatomical treatment. Evidence for ileal bile acid transporter inhibitors supports indication-specific relief of cholestatic pruritus. Recent trials of receptor agonists show that biochemical, symptomatic, and disease-progression outcomes can diverge. Observational studies support biliary diversion in selected patients with inherited cholestasis, although comparisons among procedures and with drug treatment remain uncertain. The expanding genetic spectrum of progressive familial intrahepatic cholestasis and real-world treatment reports refine patient selection but provide limited evidence for long-term surgical outcomes. Bile metabolomics and synthesis markers remain unvalidated for timing cholecystectomy. Conclusions: Molecular findings are useful when they answer a defined diagnostic or therapeutic question. They can guide specialist treatment and surveillance alongside anatomical assessment. Prospective studies must establish whether molecular stratification improves outcomes in biliary surgical populations.

  • Open Access

    Asymptomatic Cholecystitis: The Versatility of a Simple Clinical Question

    by Sergey Yurievich Muraviev, Mehrshad Ebrahimnezhad

    There is uncertainty in the surgical tactics for asymptomatic cholecystitis due to the lack of a unified understanding and variability of the causes affecting differential diagnostics when setting indications for cholecystectomy, leading to errors and the development of postcholecystectomy syndrome. We examined 252 patients with asymptomatic cholecystitis. Single stones were present in 36.9%, and multiple stones – in 45.6%. In 19.8%, there are difficulties with ultrasound visualization, which is why there are errors in identifying signs of chronic inflammation in the gallbladder. Thickened walls of the gallbladder were observed in 72.4% with diseases of the stomach. In 70.5% with the papilla of Vater, considering the presence of this pathology, lipids changed. When assessing pancreatic elastase, moderate pancreatic insufficiency was detected in 47.6% and severe insufficiency in 9.1%. The pancreas was heterogeneous in 64.3% and had calcifications in 18.3% and ductal calcifications in 7.5%. Dilation of the common bile duct by more than 6 mm was observed in 27%, and signs of choledocholithiasis were observed in 16.7%. This led to the fact that in 25% of cases, postcholecystectomy syndrome developed. It is necessary to understand the terminology of asymptomatic cholecystitis and conduct coordinated studies to reduce the frequency of unnecessary cholecystectomies and complications.